American Institute for Advanced Investment Management LLP Sells 115 Shares of Amgen Inc. (NASDAQ:AMGN)

American Institute for Advanced Investment Management LLP decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 14.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 695 shares of the medical research company’s stock after selling 115 shares during the quarter. American Institute for Advanced Investment Management LLP’s holdings in Amgen were worth $200,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Roundview Capital LLC lifted its position in shares of Amgen by 1.3% during the 1st quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock worth $2,027,000 after buying an additional 107 shares during the period. Merit Financial Group LLC increased its holdings in Amgen by 39.2% during the 1st quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after purchasing an additional 647 shares in the last quarter. Ergoteles LLC acquired a new stake in Amgen during the 1st quarter valued at $219,000. First Western Trust Bank acquired a new stake in Amgen during the 1st quarter valued at $334,000. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Amgen by 2.1% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after purchasing an additional 513 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock opened at $274.42 on Thursday. The business’s 50-day moving average price is $287.38 and its two-hundred day moving average price is $281.40. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a market cap of $147.07 billion, a PE ratio of 21.97, a P/E/G ratio of 2.67 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.09 earnings per share. As a group, research analysts forecast that Amgen Inc. will post 19.48 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AMGN shares. Raymond James started coverage on Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating for the company. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and lifted their target price for the company from $264.00 to $320.00 in a research note on Thursday, December 21st. BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Finally, The Goldman Sachs Group raised their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $295.30.

Get Our Latest Research Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.